Profil
Michel Janicot worked as a Senior Director in Oncology Scientific Licensing at Johnson & Johnson and as a Senior Director in Research & Development at Janssen, Inc. Prior to that, he was the Head of Preclinical Research & Development at Isarna Therapeutics GmbH.
He also worked as a Principal at Rhone-Poulenc Rorer Pharmaceuticals, Inc. Dr. Janicot earned a doctorate degree from Université Paris Diderot-Paris 7 in 1988.
Ehemalige bekannte Positionen von Michel Janicot
| Unternehmen | Position | Ende |
|---|---|---|
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michel Janicot
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
| Rhone-Poulenc Rorer Pharmaceuticals, Inc. | |
| Université Paris Diderot-Paris 7 | Consumer Services |
Janssen, Inc.
Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Health Technology |
